Synthesis and evaluation of novel antifungal agents-quinoline and pyridine amide derivatives

Autor: Nakamoto, Kazutaka, Tsukada, Itaru, Tanaka, Keigo, Matsukura, Masayuki, Haneda, Toru, Inoue, Satoshi, Murai, Norio, Abe, Shinya, Ueda, Norihiro, Miyazaki, Mamiko, Watanabe, Naoaki, Asada, Makoto, Yoshimatsu, Kentaro, Hata, Katsura

Publikováno v: In Bioorganic & Medicinal Chemistry Letters 1 August 2010 20(15):4624-4626

MULTIPERIOD INSURANCE CONTRACTS UNDER ASYMMETRIC INFORMATION

Autor: HANEDA, Toru

Publikováno v: Keio economic studies. 23(2):61-76

This paper examines the role of multiperiod insurance arrangements in alleviating the inefficiency associated with the adverse selection problem, in the case of both private insurance and public insurance. We argue that the inefficiency can reduced b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::d9a7333c306df73feef4ccd863355020
https://koara.lib.keio.ac.jp/xoonips/modules/xoonips/detail.php?koara_id=AA00260492-19860002-0061

Une Tablette du Decret Sacre de L'empereur Genghis

Autor: HANEDA, Toru

Publikováno v: Memoirs of the Research Department of the Toyo Bunko (The Oriental Library). 8:85-91

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=jairo_______::22026c25be9f54fc0cf85e804a5267e7
http://id.nii.ac.jp/1629/00003438/

Stereospecific synthesis of carbocyclic analogue of oxazinomycin by retrograde aldol C–C bond fission under reductive conditions.

Autor: Katagiri, Nobuya, Tomura, Michio, Haneda, Toru, Kaneko, Chikara

Publikováno v: Journal of the Chemical Society, Chemical Communications; 10/1/1987, Issue 19, p1422-1423, 2p

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.

Autor: Yamamoto Y; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Matsui J; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Matsushima T; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Obaishi H; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Miyazaki K; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Nakamura K; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Tohyama O; Biomarkers and Personalized Medicine Core Function Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Semba T; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Yamaguchi A; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Hoshi SS; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Mimura F; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Haneda T; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Fukuda Y; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Kamata JI; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Takahashi K; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Matsukura M; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Wakabayashi T; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Asada M; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Nomoto KI; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Watanabe T; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Dezso Z; Biomarkers and Personalized Medicine Core Function Unit, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810, U.S.A., Yoshimatsu K; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan., Funahashi Y; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.; Biomarkers and Personalized Medicine Core Function Unit, Eisai Product Creation Systems, Eisai Inc., 4 Corporate Drive, Andover, MA 01810, U.S.A., Tsuruoka A; Oncology Product Creation Unit, Eisai Product Creation Systems, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan.

Publikováno v: Vascular cell [Vasc Cell] 2014 Sep 06; Vol. 6, pp. 18. Date of Electronic Publication: 2014 Sep 06 (Print Publication: 2014).